Novartis (NVS.US) neuroimmunology pipeline sees mixed results: CAR-T clinical trial suspended due to patient death, while late-stage trial for oral MS drug succeeds.

智通财经2026/09/01 07:51

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

JitTong Finance APP has learned that Novartis (NVS.US) is experiencing a "mixed bag" in the neurological and autoimmune field: the company has urgently suspended eight CAR-T therapy clinical trials due to the deaths of three patients; however, its oral multiple sclerosis (MS) drug remibrutinib has achieved positive results in late-stage clinical trials.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Novartis (NVS.US) neuroimmunology pipeline sees mixed results: CAR-T clinical trial suspended due to patient death, while late-stage trial for oral MS drug succeeds.

You may also like

Crypto prices